Prul Pharmaceuticals: A holding subsidiary has obtained the drug registration certificate for ephedrine sulfate injection and the chemical raw material drug market approval notification for ephedrine sulfate raw material.

Sina Finance News on March 30th, Puruo Pharmaceuticals announced that its subsidiary Zhejiang Puruo Kangyu Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" for ephedrine sulfate injection issued by the National Medical Products Administration, as well as the "Chemical Raw Material Drug Market Approval Notice" for ephedrine sulfate raw material. The ephedrine sulfate injection is the first in China to be approved for market launch, equivalent to passing the generic drug consistency evaluation. This drug is used to treat clinically significant hypotension occurring under anesthesia. The approval for the ephedrine sulfate raw material to enter the market and the ephedrine sulfate injection obtaining the drug registration certificate reflects the company's synergistic strategy of integrating raw materials and formulations, which will enhance the market competitiveness of the products and further enrich the company's product pipeline, playing a positive role in the company's business development.